EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL

被引：0
|
作者：
Gettinger, Scott [1 ]
Horn, Leora [2 ]
Antonia, Scott J. [3 ]
Spigel, David R. [4 ]
Gandhi, Leena [5 ]
Sequist, Lecia V. [6 ]
Sankar, Vindira [7 ]
Ahlers, Christoph M. [7 ]
Wigginton, Jon M. [7 ]
Kollia, Georgia [7 ]
Gupta, Ashok [7 ]
Brahmer, Julie R. [8 ]
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Bristol Myers Squibb Co, New York, NY 10154 USA
[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
programmed death-1 receptor; nivolumab; NSCLC; subpopulations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.11-038
引用
收藏
页码：S909 / S909
页数：1
相关论文
共 50 条
  • [1] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Gulley, James L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 403 - 405
  • [2] CLINICAL ACTIVITY, SAFETY AND SUBPOPULATION RESPONSE ANALYSIS OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS (PT) WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Brahmer, J. R.
    Horn, L.
    Antonia, S. J.
    Spigel, D. R.
    Sequist, L. V.
    Ahlers, C. M.
    Sankar, V.
    Kollia, G.
    Gettinger, S.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S39 - S39
  • [3] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher T.
    Kollia, Georgia D.
    Brahmer, Julie R.
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
  • [4] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
  • [5] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Ramalingam, S. S.
    Mazieres, J.
    Planchard, D.
    Stinchcombe, T. E.
    Dy, G. K.
    Antonia, S. J.
    Horn, L.
    Lena, H.
    Minenza, E.
    Mennecier, B.
    Otterson, G. A.
    Campos, L. T.
    Gandara, D. R.
    Levy, B. P.
    Nair, S. G.
    Zalcman, G.
    Wolf, J.
    Baudelet, C.
    Lestini, B. J.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
  • [6] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Gettinger, S.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J. R.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Ready, N. E.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
  • [7] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
    Borghaei, Hossein
    Lynch, Thomas James
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Reilly, Robert
    Crino, Lucio
    Buyse, Marc E.
    Ezzeddine, Rana
    Lestini, Brian Joseph
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): OVERALL SURVIVAL AND LONG-TERM SAFETY IN A PHASE 1 TRIAL
    Brahmer, Julie R.
    Horn, Leora
    Antonia, Scott J.
    Spigel, David
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S365 - S366
  • [9] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [10] Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
    Brahmer, Julie R.
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345